RxDoctor Payments Data

Gianna Lombari

Family · Commack, NYNPI 1255007944

Payments from drug & device makers

$16,112in general payments, 2019–2025

Across 692 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Arcutis Biotherapeutics, Inc.$2K
  • Johnson & Johnson$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Novartis$1K
  • Pfizer$1K
  • plus $7K from 20 others

What the payments were for

  • Consulting fees$5003%
  • Food & beverage$15,26795%
  • Education$3452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,112 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$112,917
Medicare patients
312
Services billed
3,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab23$153,359
OpzeluraRuxolitinib Phosphate14$40,240
Tacrolimus50$5,730
Ketoconazole215$3,042
Clindamycin Phosphate41$2,245
Clobetasol Propionate49$2,030
Ammonium Lactate78$1,676
Triamcinolone Acetonide116$1,471
Fluocinonide39$1,398
Tretinoin23$1,337
Mometasone Furoate39$869
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip25$672
Metronidazole16$650
Mupirocin57$349
Hydrocortisone38$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$984$40,24014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Commack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →